Moberg Pharma Management
Management criteria checks 2/4
Moberg Pharma's CEO is Anna Ljung, appointed in May 2019, has a tenure of 7.08 years. total yearly compensation is SEK4.61M, comprised of 48.2% salary and 51.8% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $75.14K. The average tenure of the management team and the board of directors is 7.3 years and 0.4 years respectively.
Key information
Anna Ljung
Chief executive officer
SEK 4.6m
Total compensation
| CEO salary percentage | 48.22% |
| CEO tenure | 7.1yrs |
| CEO ownership | 0.1% |
| Management average tenure | 7.3yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -SEK 26m |
| Dec 31 2025 | SEK 5m | SEK 2m | -SEK 27m |
| Sep 30 2025 | n/a | n/a | -SEK 258m |
| Jun 30 2025 | n/a | n/a | -SEK 255m |
| Mar 31 2025 | n/a | n/a | -SEK 251m |
| Dec 31 2024 | SEK 4m | SEK 2m | -SEK 255m |
| Sep 30 2024 | n/a | n/a | -SEK 18m |
| Jun 30 2024 | n/a | n/a | -SEK 23m |
| Mar 31 2024 | n/a | n/a | -SEK 23m |
| Dec 31 2023 | SEK 4m | SEK 2m | -SEK 21m |
| Sep 30 2023 | n/a | n/a | -SEK 18m |
| Jun 30 2023 | n/a | n/a | -SEK 16m |
| Mar 31 2023 | n/a | n/a | -SEK 16m |
| Dec 31 2022 | SEK 3m | SEK 2m | -SEK 16m |
| Sep 30 2022 | n/a | n/a | -SEK 17m |
| Jun 30 2022 | n/a | n/a | -SEK 16m |
| Mar 31 2022 | n/a | n/a | -SEK 16m |
| Dec 31 2021 | SEK 2m | SEK 1m | -SEK 16m |
| Sep 30 2021 | n/a | n/a | SEK 8m |
| Jun 30 2021 | n/a | n/a | SEK 7m |
| Mar 31 2021 | n/a | n/a | SEK 5m |
| Dec 31 2020 | SEK 3m | SEK 2m | SEK 7m |
| Jun 30 2020 | n/a | n/a | SEK 20m |
| Jun 30 2019 | SEK 476k | SEK 151k | -SEK 8m |
Compensation vs Market: Anna's total compensation ($USD491.56K) is about average for companies of similar size in the US market ($USD635.09K).
Compensation vs Earnings: Anna's compensation has increased whilst the company is unprofitable.
CEO
Anna Ljung (46 yo)
Ms. Anna Ljung M.Sc. Econ., BA is Chief Executive Officer of Moberg Pharma AB (publ) since May 16, 2019. She was Chief Financial Officer of Moberg Pharma AB (publ) until May 16, 2019. Ms. Ljung, serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 7.1yrs | SEK 4.61m | 0.15% $ 75.1k | |
| Co-Founder | 20.3yrs | SEK 193.70k | no data | |
| Vice President of Finance & CFO | 6.7yrs | no data | 0.19% $ 95.7k | |
| Chief Scientific Officer | no data | no data | no data | |
| Senior Director of Sales & Marketing | 7.4yrs | no data | no data |
Experienced Management: MBGP.F's management team is seasoned and experienced (7.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.1yrs | SEK 111.00k | 0.012% $ 6.2k | |
| Independent Chairman | less than a year | no data | no data | |
| Independent Director | less than a year | SEK 48.00k | 1.97% $ 996.8k | |
| Independent Director | 1.1yrs | SEK 111.00k | 5.64% $ 2.9m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: MBGP.F's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 04:13 |
| End of Day Share Price | 2026/06/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Moberg Pharma AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Klas Pyk | Nordea Markets |
| Mats Hyttinge | Redeye |